KeChow Pharma’s Keluping, First NRAS Mutant Melanoma Therapy, Hits the Market

Shanghai-based KeChow Pharma has announced the official market launch of its groundbreaking drug, Keluping (tunlametinib), the world’s first targeted therapy designed specifically for NRAS mutant melanoma. Tunlametinib, a novel ATP noncompetitive MEK inhibitor that targets NRAS mutations, received marketing approval in China in March this year. The drug was granted conditional approval with priority review status, marking it as the first domestically developed MEK inhibitor in the country.- Flcube.com